Related Experiment Video
Updated: Jan 21, 2026
05:52
Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
Published on: June 30, 2011
20.3K
[Insulin therapy-new insulin analogues]
1Medizinische Klinik I, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Deutschland. marianne.ehren@bergmannsheil.de.
Der Internist
|August 10, 2019
Summary
Short-acting and long-acting insulin analogues improve diabetes mellitus treatment by mimicking natural insulin secretion. Newer analogues offer enhanced glucose control and reduced hypoglycemia risk, with future developments aiming for faster action and longer duration.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Diabetes mellitus treatment relies on insulin therapy.
- Insulin analogues offer improved pharmacokinetic and pharmacodynamic profiles compared to human insulin.
- Current insulin analogues include short-acting and long-acting formulations.
Purpose of the Study:
- To review the current landscape of insulin analogues for diabetes treatment.
- To highlight the benefits of ultrarapid and newer long-acting insulin analogues.
- To discuss future directions in insulin analogue development.
Main Methods:
- Literature review of available insulin analogues.
- Analysis of clinical data on efficacy and safety.
- Discussion of emerging trends in insulin therapy.
Main Results:
- Ultrarapid insulin analogues effectively reduce postprandial glucose excursions.
- Newer long-acting insulin analogues provide stable action profiles and lower hypoglycemia rates, particularly nocturnal hypoglycemia.
- First-generation long-acting analogues are surpassed by newer formulations in safety and efficacy.
Conclusions:
- Insulin analogues represent a significant advancement in diabetes management.
- Continued innovation in insulin analogue development promises further improvements in glycemic control and patient safety.
- Future research focuses on optimizing prandial and basal insulin action for better physiological mimicry.
Related Concept Videos
01:05Insulin Secretory Vesicles
6.4K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.4K
01:28Insulin: The Receptor and Signaling Pathways
2.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.8K
01:27Insulin Formulations: Types and Delivery
666
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
666
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.3K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.3K
01:16Insulin: Dosing Regimen and Adverse Effects
703
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
703
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K